Vivo Capital is a healthcare focused investment firm formed in 1996 with over $1 billion under management. Vivo Capital makes investments from its $375M seventh fund into private and public healthcare companies in the U.S. and greater China. Vivo Capital has offices in Palo Alto, California, Shanghai, Chengdu, and Beijing, China.
Vivo's portfolio includes more than 80 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices. Vivo Capital has made 105 investments and has raised a total of $5.4B across 8 funds.
Vivo making investments from its $1.4B Vivo Capital Fund IX into private healthcare companies, from its $635M Vivo Opportunity Fund into public healthcare companies, and from its $100M Vivo Innovation (PANDA) Fund into early-stage healthcare companies.
Vivo Capital Fund IX
Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Their growth capital investments help portfolio companies accelerate revenue ramp or fund product development to drive value creation. Their private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. They invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China.
Vivo Opportunity Fund
Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs.
Vivo Innovation Fund
Vivo Innovation Fund (i.e., Vivo PANDA Fund) focuses on investing in venture stage companies with the potential to develop healthcare technologies or products. The fund typically invests in early stage (i.e. Series A) financing rounds.
Precision BioSciences is a biotechnology developing a gene editing platform for the creation of cell therapies, gene therapies, and agricultural products.
Harmony Biosciences is a private biopharmaceutical company that develops and commercializes novel treatment options.
A clinical-stage biopharmaceutical company in Jiangsu, China that focuses on developing and commercializing oncology drugs and therapies.
Now known as Sierra Oncology, is a clinical stage drug development company in Vancouver that focuses on cancer and hematology treatments.
A clinical late-stage biopharmaceutical company in California that focuses on treatments of dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.
A clinical-stage pharmaceutical company in Colorado that focuses on treatments for refractory epilepsy.
A clinical-stage biopharmaceutical company in California that focuses developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.
A biotechnology company in California that focuses on developing, manufacturing and commercializing biologic therapeutics or biosimilars for oncology and inflammatory diseases.
A biotechnology company in Massachusetts that focuses on developing technology to produce donor-independent human platelets from human induced pluripotent stem cells.
A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.
Nora Therapeutics is a specialty biopharmaceutical company developing therapeutics to address clinical unmet needs in reproductive medicine.
Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
ALX Oncology is a Burlingame, California-based biotechnology company working on pre-clinical stage immuno-oncology therapies.
Crinetics Pharmaceuticals is a San Diego-based company founded in 2008 by Scott Struthers, Stephen F. Betz and Yun-Fei Zhu.
Maculogix is a Harrisburg, Pennsylvania-based diagnostics company focused on detection and tracking age-related macular degeneration.
Verona Pharma is a London-based biotechnology company working to discover new drugs for the treatment of chronic respiratory diseases.
Genetron Health is a Durham, North Carolina-based medical diagnostics company developing medical devices for diagnostics.
REVOLUTION Medicines is a Redwood City, California-based company.